key: cord-1044678-ozmgm5bx authors: De Melo, Guilherme Dias; Lazarini, Françoise; Levallois, Sylvain; Hautefort, Charlotte; Michel, Vincent; Larrous, Florence; Verillaud, Benjamin; Aparicio, Caroline; Wagner, Sebastien; Gheusi, Gilles; Kergoat, Lauriane; Kornobis, Etienne; Cokelaer, Thomas; Hervochon, Rémi; Madec, Yoann; Roze, Emmanuel; Salmon, Dominique; Bourhy, Hervé; Lecuit, Marc; Lledo, Pierre-Marie title: COVID-19-associated olfactory dysfunction reveals SARS-CoV-2 neuroinvasion and persistence in the olfactory system date: 2020-11-18 journal: bioRxiv DOI: 10.1101/2020.11.18.388819 sha: 9e4a2448ac1e8d915b9c830bd7f6b1a5beb0ccfb doc_id: 1044678 cord_uid: ozmgm5bx While recent investigations have revealed viral, inflammatory and vascular factors involved in SARS-CoV-2 lung pathogenesis, the pathophysiology of neurological disorders in COVID-19 remains poorly understood. Yet, olfactory and taste dysfunction are rather common in COVID-19, especially in pauci-symptomatic patients which constitutes the most frequent clinical manifestation of the infection. We conducted a virologic, molecular, and cellular study of the olfactory system from COVID-19 patients presenting acute loss of smell, and report evidence that the olfactory epithelium represents a highly significant infection site where multiple cell types, including olfactory sensory neurons, support cells and immune cells, are infected. Viral replication in the olfactory epithelium is associated with local inflammation. Furthermore, we show that SARS-CoV-2 induces acute anosmia and ageusia in golden Syrian hamsters, both lasting as long as the virus remains in the olfactory epithelium and the olfactory bulb. Finally, olfactory mucosa sampling in COVID-19 patients presenting with persistent loss of smell reveals the presence of virus transcripts and of SARS-CoV-2-infected cells, together with protracted inflammation. Viral persistence in the olfactory epithelium therefore provides a potential mechanism for prolonged or relapsing symptoms of COVID-19, such as loss of smell, which should be considered for optimal medical management and future therapeutic strategies. 3 Introduction 59 COVID-19, caused by SARS-CoV-2 commonly induces airway and pulmonary symptoms, and in 60 severe cases leads to respiratory distress and death (1) . While COVID-19 is primarily regarded as a 61 respiratory disease, many patients exhibit extra-respiratory symptoms of various severity. Among these, Table 1 . The time from first COVID-19 related symptoms to inclusion in the study ranged from 1 to 13 119 days. None of the patients required hospitalization. Their prominent symptom was recent loss of 120 olfactory function (sudden for 4 patients but progressive for case #1) and was accompanied with taste 121 changes (except case #3) and at least one symptom belonging to the clinical spectrum of COVID-19, 122 such as diarrhea, cough, dyspnea, conjunctivitis, fever, fatigue, headache, muscle pain, laryngitis or a 123 sore throat (Supplemental Figure S1A ). Olfactory function loss was the first symptom related to 124 COVID-19 in case #5 while it was preceded by, or concomitant with other symptoms in the remaining 125 patients. Smell loss was deemed severe for cases #1, #2, #4 and #5, and moderate for case #3. Taste 126 loss was deemed severe for cases #1, #2, #4 and #5, and mild for case #3. The characteristics of the 127 taste and smell abnormalities are listed in Supplemental Table S1 . Other otolaryngologic symptoms 128 were rhinorrhea for 4 patients, not concomitant with smell loss, nasal irritation for 2 patients and 129 hyperacusis for case #1. Nasal obstruction was not reported in any of the patients. Taste changes were 130 characterized in the 4 patients by dysgeusia where they had a reduced acuity for sweet taste, had a bad 131 taste in the mouth, reduced or increased acuity for bitter, reduced acuity for salt or sour were reported 132 in 3 out of the 4 patients with dysgeusia. Two patients (#2 and #4) were unable to discriminate between 133 different foods such as meat and fish. To investigate whether infection in the olfactory mucosa is associated with olfactory functional 135 loss, all patients underwent olfactory mucosa brush cytological sampling. Only two patients had 136 detectable SARS-CoV-2 RNA, using the conventional nasopharyngeal samples at inclusion (Table 1). 137 However, all patients -but none of the controls -had detectable SARS-CoV-2 RNA in cytological 138 samples from the olfactory mucosa using the RT-qPCR SYBR green technique, unambiguously 139 6 confirming the diagnosis of COVID-19 (Table 1) . Patient #2 had a strong viral load in the olfactory 140 mucosa (2.25. 10 6 RNA copies/µL), while other cases were positive (RT-qPCR SYBR green) but not 141 quantifiable (less 200 RNA copies/µL using the RT-qPCR Taqman technique). We further investigated the viral presence in the patient's olfactory mucosa by 143 immunofluorescence labeling of the cytological samples. Variable cell density between olfactory 144 mucosa samples from the COVID-19 and control patients was found, but all samples contained mature 145 OSNs, positive for OMP, validating the quality of the swabbing procedure ( Figure 1 , A and B and 146 Supplemental Figure S1B ). Immunostaining revealed the presence of SARS-CoV-2 antigens 147 (nucleoprotein, NP) in 3 patients (RT-qPCR+) out of 5 but not in controls (Table 1, Figure 1 ). We 148 observed numerous Iba1 + cells in the olfactory mucosa of all patients whereas few to no Iba1 + cells in 149 controls (Table 1 ; Figure 1E and Supplemental Figure S1D ). These data suggest that SARS-CoV-2 150 infection is associated with inflammation of the olfactory mucosa in patients with olfactory impairment, 151 thus we measured the profile of local cytokine and inflammatory mediators (Table 1) . Whereas there 152 was no change in the transcript levels of Ccl5, Cxcl10, Isg20 and Mx1 genes as compared to controls, 153 transcript levels for the proinflammatory cytokine IL6 were elevated in the 3 patients with detectable 154 SARS-CoV-2 antigens as compared to control patients, and the 2 other patients positive for CoV-2 155 RNA but without detectable CoV-2 antigens (Table 1) . Together, this first set of data indicates that SARS-CoV-2 exhibits a clear tropism for the 157 olfactory epithelium, and this infection is associated with increased local inflammation. We next 158 investigated the identity of the cell types targeted by SARS-CoV-2. We detected SARS-CoV-2-infected 159 mature sensory neurons (OMP + ; Figure 1 , B and C); other SARS-CoV-2 infected cells were 160 sustentacular cells (expressing CK18, see Figure 1D and Supplemental Figure S1C ), and myeloid cells 161 (expressing Iba1, Figure 1E ). We detected the presence of several immature sensory neurons (Tuj-1 + ) 162 in the olfactory mucosa of all patients, some of them being infected. Interestingly, some Iba1 and SARS-163 CoV-2 positive cells were engulfing portions of Tuj-1 cells in the olfactory mucosa of COVID case #2, 164 suggesting that infected immature sensory neurons were in the process of being phagocytosed by brain 165 innate immune cells ( Figure 1E ). These results show that a variety of cell types are infected in the 166 olfactory epithelium of COVID-19 patients. Among them, the mature OSN are critically relevant in the 7 context of the anosmia. To assess the impact of the neuroepithelium infection by SARS-CoV-2, we 168 infected Syrian golden hamsters to experimentally reproduce anosmia and ageusia, and investigate the 169 potential SARS-CoV-2 infection of the olfactory system and upstream brain tissues. Figure S3 ). At 4 dpi, viral particles were seen budding from deciliated cells ( Figure 4D ). At 14 dpi, the olfactory mucosa appeared ciliated anew, indistinguishable from that of mock-infected 210 animals ( Figure 4E and Supplemental Figure S3 ), consistent with the recovery of olfaction seen in 211 infected hamsters ( Figure 3C ). In line with the detection of viral particles by electron microscopy at 4 dpi, SARS-CoV-2 213 immunostaining was detected in the hamsters' olfactory mucosa at this time point which was associated 214 with an infiltration of myeloid Iba1 + cells ( Figure 5 , B-E). In the olfactory mucosa, SARS-CoV-2 215 antigens were found in the cytoplasm of mature (OMP + ; Figure 5B ) and immature (Tuj1 + ; Figure 5D ) 216 sensory neurons and in sustentacular cells (CK18 + ; Supplemental Figure S4B ). Some Iba1 + immune 217 cells seen infiltrating the neuroepithelium were positive for SARS-CoV-2, consistent with a potential 218 secondary infection resulting from the phagocytosis of infected cells ( Figure 5D , arrow). Of note, the 219 areas of neuroepithelium containing infected cells were disorganized (see Figure 5 , B and D, and 220 Supplemental Figure S4B ), while adjacent areas without SARS-CoV-2 remained stratified 221 (Supplemental Figure S4C ). Cilia of OMP + neurons located at the apical part of olfactory epithelium 222 were lost in the disorganized infected neuroepithelium (Supplemental Figure S4C ). Having shown that SARS-CoV-2 infects OSNs, and that SARS-CoV-2-infected hamsters exhibit signs 225 of anosmia and ageusia, we wondered whether SARS-CoV-2 invades the CNS via a retrograde route 226 from the olfactory system. SARS-CoV-2 was detected in olfactory nerve bundles close to the 227 neuroepithelium, as demonstrated by the co-localization of SARS-CoV-2 nucleoprotein antigen and 228 OMP + sensory neuron axons reaching the olfactory bulb ( Figure 5E ), consistent with a retrograde 229 infection of axons. Furthermore, SARS-CoV-2 nucleoprotein was detected at the junction of the 230 olfactory nerve and olfactory bulb, seemingly infecting cells of neuronal/glial morphology ( Figure 5F ). In the olfactory bulb, SARS-CoV-2 nucleoprotein was detected in Iba1+ cells ( Figure 5H based on their initial clinical assessment, including sudden anosmia at disease onset, accompanied with 275 taste changes (except case #8) and at least one clinical sign related to COVID-19, such as fever, fatigue, 276 diarrhea, cough, dyspnea, headache, muscle pain, laryngitis, sore throat, but also paresthesia and vertigo 277 in some patients ( Figure 7A ). Smell loss was complete at disease onset for these patients. Other 11 otolaryngologic symptoms were rhinorrhea for 2 patients, not concomitant with smell loss and nasal 279 irritation for 3 patients. Nasal obstruction was reported in patient #10. All had persistent smell loss, persistent taste dysfunction (except case #8) and/or other 281 neurological deficits after COVID-19 at inclusion ( Figure 7A ) and were seen at the ENT department 282 for this reason. Neurological signs were stereotypical crises of wriggling nose, left intercostal and non-283 specific arm pain (case #8), paresthesia (case #9) and vertigo (case #10). The characteristics of taste 284 and smell abnormalities at inclusion are described in Supplemental Table S2 . Two patients complained 285 of bad taste (Supplemental Table S2 ). Reduced or increased acuity for bitter, reduced acuity for salt or 286 sour were reported by the two patients with dysgeusia. None of the patients required hospitalization. All behavioral assessment was performed in isolators in a Biosafety level-3 facility that we specially 434 equipped for that. Sucrose preference test. We measured taste in hamsters by a sucrose preference test based on a two-436 bottle choice paradigm which paired 2% sucrose with regular water (48). A reduction in the sucrose 437 preference ratio in experimental infected relative to mock animal is indicative of taste abnormalities. After 6 hours water deprivation, we realized an individual overnight testing which corresponds to a 439 natural activity period of the hamster. The preference was calculated using the following formula: 440 preference = sucrose intake/total intake x 100%. The total intake value is the sum of the sucrose intake 441 value and the regular water intake Golden hamsters' gene targets were selected for quantifying host inflammatory mediators' transcripts 533 in the tissues using the Hprt (hypoxanthine phosphoribosyltransferase) and the g-actin genes as 534 reference (Table S3) Immunofluorescence of infected cells in the olfactory mucosa of the case #10 presenting with persistent olfactory dysfunction at 196 days after COVID-19 onset. The left arrow indicates an infected cell with viral NP staining. The right arrow indicates a Tuj1-NP co-labelling in another cell. (C) Graph depicting the correlation between the IL-6 mRNA expression and the viral load in the 9 patients with acute COVID-19 ("acute": n=5) or persistent olfactory dysfunction post-COVID-19 ("persistent", n=4). Viral load values were assessed by Taqman qPCR; when not quantifiable (nq: <200 copies /µL), they were arbitrary given the 50 value for Spearman test (C). Variations in the cytokine gene expression were calculated as the n-fold change in expression in the swabs compared with the swab value of control #1 that was arbitrary put on zero value. Spearman test (C). Scale bar (B): 20 µM. Sum of smell changes scores and taste changes scores; Smell changes scores from 0 normal to 5 WHO. WHO Coronavirus Disease (COVID-19) Dashboard Neurologic Features in Severe SARS-CoV-2 Infection Olfactory and Gustatory Dysfunction as an Early Identifier of COVID-19 in Adults and 603 Children: An International Multicenter Study Smell and taste dysfunction in patients with COVID-19 Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 611 Clinically Proven Protease Inhibitor SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory 613 Tract Anosmia in COVID-19: Mechanisms and Significance The Olfactory Bulb: An Immunosensory Effector Organ during Neurotropic Viral 616 Infections SARS-CoV-2 targets neurons of 3D human brain organoids Neuropathology of patients with COVID-19 in Germany: a post-mortem case series Multiorgan and Renal Tropism of SARS-CoV-2 Loss of smell in COVID-19 patients: MRI data reveals a transient edema of the olfactory 623 clefts Anosmia: an evolution of our understanding of its importance in COVID-19 and what 625 questions remain to be answered Anosmia in COVID-19 Associated with Injury to the Olfactory Bulbs Evident on 17 Bilateral transient olfactory bulb edema during COVID-19-related anosmia Spike protein recognition of mammalian ACE2 predicts the host range and an optimized 631 ACE2 for SARS-CoV-2 infection Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory 633 Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-635 Converting Enzyme 2 A Mouse Model of SARS-CoV-2 Infection and Pathogenesis SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung 639 inflammation and impaired function Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 641 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility Pathogenesis and transmission of SARS-CoV-2 in golden hamsters Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure 646 development Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan A test for Creutzfeldt-Jakob disease using nasal brushings Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection 658 or inflammatory rebound? Patterns of smell recovery in 751 patients affected by the COVID-19 660 outbreak Virological assessment of hospitalized patients with COVID-2019 Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19 Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 666 convalescent plasma donors Persistent Symptoms in Patients After Acute COVID-19 Olfactory transmucosal SARS-CoV-2 invasion as port of Central Nervous System 669 entry in COVID-19 patients COVID-19 and the Chemical Senses: Supporting Players Take Center Stage SARS-CoV-2 infection damages airway motile cilia and impairs mucociliary clearance More on Neurologic Features in Severe SARS-CoV-2 Infection Neuropathological Features of Covid-19 Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic 678 Pathogens of the Central Nervous System? Viruses Long-term consequences of COVID-19: research needs Subjective and Objective Assessment of Taste and Smell Sensation in Advanced 682 Effects of septorhinoplasty on smell perception A) Variation in total consumption of liquid overnight and preference towards 732 2% sucrose-containing water of control and SARS-CoV-2 infected hamsters at 2 dpi. (B) Fraction of 733 control or infected hamsters successfully finding hidden food in 15 minutes. (C) Fraction of control 734 or infected hamsters successfully finding hidden or visible food over time. Food-finding assays were 735 performed at 3, 5-and 14-dpi Cox) test (C). P value is indicated in bold when significant. Bars indicate medians. N=6-16 per group Grey dots represent genes not passing a threshold of FDR < 0.05. Black dots represent 758 genes passing the FDR threshold but having fold changes between -1 and 1. Red and blue dots correspond 759 to significant down and up-regulated genes with a fold change Circle color is proportional to the corrected p-values and corresponds to the scale presented 763 in C, D and E. (C). GO enrichment analysis considering biological process only. Selected GO terms are 764 based on the up and down-regulated genes between infected and non-infected samples. The black bars 765 on the right-hand side of the scatter plot indicate enrichment based on down Circle sizes are 767 proportional to the gene set size, which shows the total size of the gene set associated with GO terms GO enrichment analysis considering molecular function and cellular components related The 770 figures follow the same construction as in biological process, with the exception that only the 10 highest 771 fold enrichments are plotted for the up regulated gene set. (D) Validation targets in the olfactory bulb at 772 2, 4 and 14 dpi. n=6/time-point The p value is indicated when significant. Horizontal lines indicate the medians Olfactory bulb Single z-plane